Arkolith/Insider Trading/URGN/Form 4

Schoenberg Mark

Chief Medical OfficerUroGen Pharma Ltd. (URGN) · full profile →Form 4 · filed Feb 4, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$51K
Net Open-Market Flow
-$51K
Transactions
10
6 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2025Option exercise(M)3K——150K
Jan 31, 2025Sell(S)2K$11.14$21K147K
Jan 31, 2025Option exercise(M)3K——149K
Jan 31, 2025Sell(S)759$11.14$8K146K
Jan 31, 2025Option exercise(M)1K——146K
Jan 31, 2025Sell(S)2K$11.14$21K149K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2025Option exercise(M)1K—$00
Jan 31, 2025Option exercise(M)3K—$03K
Jan 31, 2025Option exercise(M)3K—$07K
Jan 31, 2025Grant(A)20K—$020K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-25-002688) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML